Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKTive-001: ALTA2618 in Advanced Solid Tumors with AKT1 E17K Mutation
jRCT2031240650Phase 1Active, not recruiting
- Sponsor
- Alterome Therapeutics
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tanerasertib in Nonhematologic neoplasms, sponsored by Alterome Therapeutics. Primary endpoints: Treatment-emergent adverse events and Dose-limiting toxicities. Started Jun 2025; status: active, not recruiting.
02
Drugs
tanerasertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031240650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240650.